CoChat

The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits

Ryder, R. E. J. · 2013 · Diabetic Medicine
Cited by 41

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Recent suggestions that glucagon‐like peptide‐1 (GLP‐1)‐based therapies could cause pancreatitis, and even pancreatic cancer, are based on: Animal studies: The worrying histological changes are not reproduced in all studies and are unexpectedly variable with different GLP‐1‐based therapies. An observational study: Singh's findings that pancreatitis is doubled with GLP‐1‐based therapies could relate to their use in obese patients who are prone to pancreatitis risk factors—gallstones and hypertriglyceridaemia. The other observational studies do not find an association between GLP‐1‐based therapies and pancreatitis. US Food and Drug Administration adverse event reporting system: The increased reports of pancreatitis and pancreatic cancer are likely to be attributable to ‘notoriety bias’. A study of organ donor pancreases: Butler's findings for those on GLP‐1‐based therapies vs. those not, could have other explanations. Meanwhile: Meta analysis: Randomized control trials with GLP‐1‐based therapies do not find increased pancreatitis risk. Meta‐analysis of 53 randomized controlled trials including 20 212 dipeptidyl peptidase‐4 inhibitor‐treated patients found a significantly reduced risk of major adverse cardiovascular events [odds ratio 0.689 (0.528–0.899), P = 0.006] for dipeptidyl peptidase‐4 inhibitors compared with control subjects. Cardiovascular risk: The evidence suggests that there is more than a possibility that some of the GLP‐1 receptor agonists, and possibly also some dipeptidyl peptidase‐4 inhibitors, may be associated with reduced cardiovascular events. Eight ongoing long‐term cardiovascular randomized controlled trials will report from September 2013 onwards. These trials should resolve the issue of pancreatitis risk and substantiate the extent of benefit. Conclusion: Whilst we should remain vigilant, currently the balance of evidence is strongly in support of GLP‐1‐based therapy, with benefits far outweighing potential risks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12301

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 41

Metadata

Authors
Ryder, R. E. J.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2013-09-16
Volume
30
Issue
10
Pages
1148-1155
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2103487864
Cited by
41
References
10
FWCI
4.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits. https://app.cochat.ai/papers/10.1111/dme.12301
The paper
Ryder, R. E. J. (2013). The potential risks of pancreatitis and pancreatic cancer with GLP‐1‐based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic Medicine. https://doi.org/10.1111/dme.12301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.